(Q33291042)

17635517

25 July 2017

title

Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation (English)

1 reference

25 July 2017

1 reference

1 reference

1 reference

S Diermeier

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496387&resulttype=core&format=json

14 May 2020

author name string

G Brockhoff

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496387&resulttype=core&format=json

14 May 2020

B Heckel

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496387&resulttype=core&format=json

14 May 2020

E Schmidt-Bruecken

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496387&resulttype=core&format=json

14 May 2020

M Plander

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496387&resulttype=core&format=json

14 May 2020

F Hofstaedter

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496387&resulttype=core&format=json

14 May 2020

A Vollmann

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496387&resulttype=core&format=json

14 May 2020

publication date

1 August 2007

1 reference

25 July 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496387&resulttype=core&format=json

14 May 2020

volume

40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496387&resulttype=core&format=json

14 May 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496387&resulttype=core&format=json

14 May 2020

page(s)

488-507

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496387&resulttype=core&format=json

Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells

14 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2007.00449.X

Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2007.00449.X

Exposure to continuous bromodeoxyuridine (BrdU) differentially affects cell cycle progression of human breast and bladder cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2007.00449.X

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2007.00449.X

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2007.00449.X

Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2007.00449.X

Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2007.00449.X

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2007.00449.X

Smart drugs: tyrosine kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2007.00449.X

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab

21 January 2018

1 reference

12 December 2020

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

1 reference

12 December 2020

Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab

1 reference

12 December 2020

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer

1 reference

12 December 2020

Use of novel second-line targeted therapies in non-small cell lung cancer

1 reference

12 December 2020

A Phase II Trial with Trastuzumab and Pertuzumab in Patients with HER2-Overexpressed Locally Advanced and Metastatic Breast Cancer

1 reference

12 December 2020

Targeting the epidermal growth factor receptor in colorectal cancer: advances and controversies

1 reference

12 December 2020

HER2 expression as a potential marker for response to therapy targeted to the EGFR.

1 reference

12 December 2020

Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers

1 reference

12 December 2020

Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin

1 reference

12 December 2020

Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

1 reference

12 December 2020

Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.

1 reference

12 December 2020

Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis

1 reference

12 December 2020

Cell-cycle analysis using continuous bromodeoxyuridine labeling and Hoechst 33358-ethidium bromide bivariate flow cytometry.

1 reference

12 December 2020

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

1 reference

12 December 2020

A new therapeutic antibody masks ErbB2 to its partners

1 reference

12 December 2020

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

1 reference

12 December 2020

Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225

1 reference

12 December 2020

Monoclonal antibody therapy of cancer

1 reference

12 December 2020

Targeting HER2 Epitopes

1 reference

12 December 2020

Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions

1 reference

12 December 2020

In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.

1 reference

12 December 2020

10.1111/J.1365-2184.2007.00449.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496387&resulttype=core&format=json

14 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496387&resulttype=core&format=json

14 May 2020

17635517

1 reference